Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Limited has bolstered its financial standing by receiving a $3.0 million R&D tax rebate, with an additional $0.3 million expected soon. This funding supports the company’s ongoing development of its lead cancer therapy asset, ALA-101, as it moves towards clinical trials. The Australian Government’s R&D Tax Incentive continues to provide crucial support for innovative biotech companies like Arovella.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
